<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported) July 26, 1996
--------------------
BOSTON LIFE SCIENCES, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-6533 87-0277826
------------------------------ ------ --------------------------------
(State or other jurisdiction of (Commission (I.R.S. Employer Identification
incorporation or organization) File No.) No.)
33 Newbury Street, Suite 300
Boston, Massachusetts 02116
- --------------------------------------- -----------
(Address of principal executive offices) Zip Code
Registrant's telephone number, including area code (617) 425-0200
-----------------
PAGE 1 OF 3 CONSECUTIVELY NUMBERED PAGES.
<PAGE>
Item 5. Other Events.
------------
On July 26, 1996, the Company filed a Registration Statement on Form
S-3 to register, among other things, shares of the Company's Common Stock, par
value $.01 per share, which were sold pursuant to the private placement
described more fully in the Company's Report on Form 8-K filed on July 9, 1996.
The 10,826,170 shares of the Company's Common Stock registered pursuant to this
Registration Statement will be sold by certain Selling Stockholders from time to
time. The net proceeds from the sale of these securities will be received, and
any commissions, discounts or other fees payable to broker dealers in connection
with any such sale will be borne, by the Selling Stockholders. The Company will
not receive any proceeds from the sale of these securities by the Selling
Stockholders.
Page 2 of 3
<PAGE>
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BOSTON LIFE SCIENCES, INC.
Dated: July 26, 1996 By: /s/ Marc E. Lanser, M.D.
----------------------------
Executive Vice President and
Chief Scientific Officer
Page 3 of 3
